DAX24.244 +0,2%Est505.673 +0,1%MSCI World4.343 -0,1%Top 10 Crypto14,88 -2,1%Nas23.213 +1,2%Bitcoin94.743 ±0,0%Euro1,1624 ±0,0%Öl66,63 +1,0%Gold4.129 +0,1%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Beyond Meat A2N7XQ TKMS thyssenkrupp Marine Systems TKMS00 Rheinmetall 703000 NVIDIA 918422 RENK RENK73 D-Wave Quantum A3DSV9 DroneShield A2DMAA SAP 716460 Tesla A1CX3T Intel 855681 Deutsche Telekom 555750 Infineon 623100 Lufthansa 823212 Siemens Energy ENER6Y HENSOLDT HAG000
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
Handelsstreit im Blick: DAX geht im Plus ins Wochenende -- Intel: Starke Zahlen -- HENSOLDT: Höhere Ziele -- Lufthansa, DroneShield, SuperMicro, TKMS, Beyond Meat, Dow im Fokus
Top News
Porsche-Aktie: Operativer Gewinn bricht wegen Sonderkosten ein Porsche-Aktie: Operativer Gewinn bricht wegen Sonderkosten ein
Top-News der Woche: Diese Themen waren diese Woche wichtig Top-News der Woche: Diese Themen waren diese Woche wichtig
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Precigen Aktie

Kaufen
Verkaufen
Precigen Aktien-Sparplan
3,74 EUR +0,37 EUR +10,98 %
FSE
4,48 USD +0,23 USD +5,29 %
BTT
Precigen jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 11/2024)
Smartphone

Marktkap.1,00 Mrd. EUR

Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA2PZG1

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS74017N1054

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolPGEN

Precigen Aktien News

DatumMeistgelesen
PR NewswirePrecigen to Participate in the JMP Securities Hematology and Oncology Summit
PR NewswirePrecigen Reports Third Quarter 2023 Financial Results and Progress of Clinical Programs
PR NewswirePrecigen to Participate in the Stifel 2023 Healthcare Conference
PR NewswirePrecigen to Participate in Upcoming Leading Investor and Industry Conferences
PR NewswirePrecigen Reports Second Quarter and First Half 2023 Financial Results and Provides Update on Portfolio Prioritization and Capital Allocation Strategies to Extend Projected Cash Runway into 2025
PR NewswirePrecigen Announces FDA Confirmation that the Ongoing Phase 1/2 Study of PRGN-2012 AdenoVerse Immunotherapy Will Serve as the Pivotal Study to Support Accelerated Approval
PR NewswirePrecigen to Announce Second Quarter and First Half 2023 Financial Results on August 9th
PR NewswirePrecigen Receives Breakthrough Therapy Designation for PRGN-2012 AdenoVerse™ Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis
PR NewswirePrecigen Announces Positive Phase 1 Data for PRGN-3005 Autologous UltraCAR-T® Cells Manufactured Overnight for Infusion Next Day to Advanced Stage Platinum Resistant Ovarian Cancer Patients
PR NewswirePrecigen Announces Positive Phase 1 Data for Off-the-Shelf PRGN-2009 AdenoVerse™ Immunotherapy Alone and in Combination with an Investigational Checkpoint Inhibitor in Patients with Recurrent/Meta...
PR NewswirePrecigen Receives FDA Clearance of IND to Initiate Phase 2 Study of PRGN-2009 Off-the-Shelf AdenoVerse Immunotherapy in Combination with Pembrolizumab to Treat Patients with Recurrent or Metastati...
PR NewswirePrecigen Reports First Quarter 2023 Financial Results and Business Updates
PR NewswirePrecigen to Announce First Quarter 2023 Financial Results on May 10th
PR NewswirePrecigen to Present Latest Clinical Advancements for PRGN-3005 UltraCAR-T® and PRGN-2009 Off-the-Shelf AdenoVerse™ Immunotherapy at the 2023 ASCO Annual Meeting
PR NewswirePrecigen Presents Preclinical Data for the Next Generation Mesothelin UltraCAR-T® with Intrinsic PD-1 Blockade at the AACR Annual Meeting 2023
PR NewswirePrecigen Regains Exclusive Rights to Proven CAR-T Targets, CD19 and BCMA, to Enable Unencumbered Development and Commercialization of UltraCAR-T®
PR NewswirePrecigen Announces Further Advancement of UltraCAR-T® Platform with First Patient Dosed in Phase 1/1b Dose Escalation/Dose Expansion Study of PRGN-3007 in Advanced ROR1+ Hematological and Solid Tumors
PR NewswirePrecigen to Participate in a Virtual Fireside Chat at Cantor's "The Future of Oncology" Virtual Symposium
PR NewswirePrecigen Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates
PR NewswirePrecigen Announces Positive Phase 1 Dose Escalation and Expansion Cohort Data for Investigational Off-the-Shelf PRGN-2012 AdenoVerse™ Immunotherapy in Patients with Recurrent Respiratory Papilloma...
PR NewswirePrecigen Provides Pipeline and Corporate Updates at the 41st Annual J.P. Morgan Healthcare Conference
PR NewswirePrecigen to Host a Virtual R&D Event on January 24th to Share Safety and Efficacy Data from the Phase 1 Dose Escalation and Expansion Cohorts of PRGN-2012 AdenoVerse™ Immunotherapy in Recurrent Re...
PR NewswirePrecigen to Present at the 41st Annual J.P. Morgan Healthcare Conference
PR NewswirePrecigen Announces Positive Phase 1 Dose Escalation Data for Autologous PRGN-3006 UltraCAR-T® Manufactured Overnight for Next Day Infusion in Relapsed or Refractory Acute Myeloid Leukemia Patients
PR NewswirePrecigen Reports Third Quarter 2022 Financial Results and Progress of Clinical Programs
PR NewswirePrecigen to Announce Third Quarter 2022 Financial Results on November 9th

Precigen News

Precigen News: auf dieser Seite finden Sie alle Precigen News und Nachrichten zur Precigen Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Precigen News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Precigen News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.